Email
Print
Typhoid Fever Vaccines Market - Forecast(2024 - 2030)
Typhoid Fever Vaccines Market Overview:
The Typhoid Fever Vaccines Market was valued at 3.315 billion in 2022, and is projected to reach 8.445 billion by 2030, growing at a CAGR of 12.4% from 2023 to 2030.
The Typhoid Fever Vaccines market is an integral part of global healthcare efforts to combat typhoid fever, a potentially life-threatening bacterial infection caused by Salmonella Typhi. The market comprises various vaccines designed to prevent and control the spread of the disease. These vaccines primarily include Vi polysaccharide vaccines, Ty21a vaccines, and newer conjugate vaccines.
The market has witnessed significant growth due to rising awareness about the burden of typhoid fever in low and middle-income countries, where the disease is endemic. Governments and international organizations have also intensified vaccination campaigns to reduce the disease's impact on public health. Additionally, advancements in vaccine research and development have led to the introduction of more effective and long-lasting conjugate vaccines.
However, challenges remain, such as vaccine accessibility and affordability in resource-constrained regions. Collaborations between pharmaceutical companies, governments, and non-profit organizations are essential to address these challenges and ensure wider vaccine availability. Continued efforts to strengthen healthcare infrastructure, surveillance, and vaccination programs are crucial to curbing the global impact of typhoid fever.
Market Snapshot:
Typhoid Fever Vaccines Market - Report Coverage:
The “Typhoid Fever Vaccines Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Typhoid Fever Vaccines Market.
| Attribute | Segment |
|---|---|
By Type |
|
By Application |
|
By End-user |
|
By Geography |
|
Typhoid Fever Vaccines Market - Top Trends:
Increasing Demand in Endemic Regions: There has been a growing demand for typhoid fever vaccines in regions where the disease is endemic, particularly in parts of South Asia, Southeast Asia, and Sub-Saharan Africa. As governments and healthcare organizations focus on reducing the burden of typhoid fever, vaccination campaigns have gained momentum.
Adoption of Conjugate Vaccines: Conjugate vaccines, which provide longer-lasting immunity and are effective in younger age groups, have gained traction in the market. These vaccines have shown promising results in preventing typhoid fever, and their adoption is expected to increase in the coming years.
Government Immunization Programs: Many governments have intensified their efforts to include typhoid fever vaccination in their routine immunization programs. This integration Technological Advancements: Advancements in vaccine production techniques and technologies have contributed to the development of more efficient and cost-effective typhoid fever vaccines.
Combination Vaccines: Manufacturers have explored the possibility of developing combination vaccines that offer protection against multiple diseases, including typhoid fever. These combination vaccines can streamline immunization efforts and improve overall vaccine compliance.
Technological Advancements: Advancements in vaccine production techniques and technologies have contributed to the development of more efficient and cost-effective typhoid fever vaccines.
The Typhoid Fever Vaccines Market - Company Analysis:
Bharat Biotech International Limited: Headquartered in India, Bharat Biotech is a leading vaccine manufacturer and has been actively involved in the development and production of typhoid fever vaccines, including the Vi polysaccharide vaccine.
GlaxoSmithKline plc (GSK): GSK, a UK-based multinational pharmaceutical company, has a strong presence in the vaccines market. They have developed and marketed typhoid fever vaccines, including Vi polysaccharide vaccines.
Sanofi Pasteur: As the vaccine division of Sanofi, a global pharmaceutical company based in France, Sanofi Pasteur has been involved in producing vaccines to combat various infectious diseases, including typhoid fever.
Takeda Pharmaceutical Company Limited: Takeda, headquartered in Japan, has also been actively involved in developing typhoid fever vaccines, including the Vi polysaccharide vaccine.
Merck & Co., Inc.: Merck, a major US-based pharmaceutical company, has a history of vaccine development and production. They have been involved in research and development related to typhoid fever vaccines.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships, and collaborations are key strategies adopted by players in the are key strategies adopted by players in the Typhoid Fever Vaccines Market Report. The top 10 companies in this industry are listed below:
Shanghai Institute of Biological Products Co., Ltd.
Bharat Biotech
Sanofi
GlaxoSmithKline
Paxvax Inc.
Prokarium Ltd.
Scandinavian Biopharma
China National Biotec Group
PT Bio Farma
Takeda Pharmaceutical
l Scope of Report:
| Report Metric | Details |
|---|---|
Base Year Considered | 2022 |
Forecast Period | 2023 – 2030 |
CAGR | 12.4% |
Market Size in 2030 | 8.445 million |
Segments Covered | By Type, By Application, By End user, By Geography |
Geographies Covered |
|
Key Market Players |
|
For more Energy and Power Market reports, please click here
1. Typhoid Fever Vaccines Market - Overview
1.1. Definitions and Scope
2. Typhoid Fever Vaccines Market - Executive Summary
3. Typhoid Fever Vaccines Market - Comparative Analysis
3.1. Company Benchmarking - Key Companies
3.2. Global Financial Analysis - Key Companies
3.3. Market Share Analysis - Key Companies
3.4. Patent Analysis
3.5. Pricing Analysis
4. Typhoid Fever Vaccines Market - Start-up Companies Scenario (Premium)
4.1. Key Start-up Company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Venture Capital and Funding Scenario
5. Typhoid Fever Vaccines Market – Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing Business Index
5.3. Case Studies of Successful Ventures
6. Typhoid Fever Vaccines Market - Forces
6.1. Market Drivers
6.2. Market Constraints
6.3. Market Challenges
6.4. Porter's Five Force Model
6.4.1. Bargaining Power of Suppliers
6.4.2. Bargaining Powers of Customers
6.4.3. Threat of New Entrants
6.4.4. Rivalry Among Existing Players
6.4.5. Threat of Substitutes
7. Typhoid Fever Vaccines Market – Strategic Analysis
7.1. Value Chain Analysis
7.2. Opportunities Analysis
7.3. Market Life Cycle
8. Typhoid Fever Vaccines Market – By Type (Market Size – $Million/$Billion)
8.1. Live Attenuated Vaccine
8.1.1. Market Trends by Region
8.1.2. Market Share & Forecast by Region
8.2. Capsular Polysaccharide Vaccine
8.2.1. Market Trends by Region
8.2.2. Market Share & Forecast by Region
8.3. Conjugate Vaccine
8.3.1. Market Share & Forecast by Region
8.3.2. Market Share & Forecast by Region
8.4. Others
9. Typhoid Fever Vaccines Market – By Application (Market Size – $Million/$Billion)
9.1. Oral
9.1.1. Market Trends by Region
9.1.2. Market Share & Forecast by Region
9.2. Injection
9.2.1. Market Trends by Region
9.2.2. Market Share & Forecast by Region
10. Typhoid Fever Vaccines Market – By End-User (Market Size – $Million/$Billion)
10.1. Hospitals and Clinics
10.1.1. Market Trends by Region
10.1.2. Market Share & Forecast by Region
10.2. Specialty Centers
10.2.1. Market Trends by Region
10.2.2. Market Share & Forecast by Region
11. Typhoid Fever Vaccines Market – by Geography (Market Size – $Million/$Billion)
11.1. North America
11.1.1. The U.S.
11.1.2. Canada
11.2. Europe
11.2.1. UK
11.2.2. Germany
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Asia-Pacific
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. South Korea
11.3.5. Australia & New Zealand
11.3.6. Rest of Asia-Pacific
11.4. South America
11.4.1. Brazil
11.4.2. Argentina
11.4.3. Chile
11.4.4. Colombia
11.4.5. Rest of South America
11.5. Rest of the World
11.5.1. Middle East
11.5.2. Africa
12. Typhoid Fever Vaccines Market – Entropy
13. Typhoid Fever Vaccines Market – Industry/Segment Competition Landscape Premium
13.1. Market Share Analysis
13.1.1. Market Share by Product Type – Key Companies
13.1.2. Market Share by Region – Key Companies
13.1.3. Market Share by Country – Key Companies
13.2. Competition Matrix
13.3. Best Practices for Companies
14. Typhoid Fever Vaccines Market – Key Company List by Country Premium
15. Typhoid Fever Vaccines Market - Company Analysis
15.1. Shanghai Institute Of Biological Products Co., Ltd.
15.2. Bharat Biotech
15.3. Sanofi
15.4. GlaxoSmithKline
15.5. Paxvax Inc.
15.6. Prokarium Ltd.
15.7. Scandinavian Biopharma
15.8. China National Biotec Group
15.9. PT Bio Farma
15.10. Takeda Pharmaceutical
15.11. Merck & Co., Inc.
15.12. Valneva SE
15.13. Biological E. Limited
15.14. Novartis AG
15.15. Emergent BioSolutions Inc.
15.16. Panacea Biotec Ltd.
15.17. SK Chemicals Co., Ltd
15.18. Indian Immunologicals Ltd.
15.19. Shantha Biotechnics Private Limited
15.20. Walvax Biotechnology Co., Ltd.
"Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape.
The Typhoid Fever Vaccines Market is projected to grow at 12.4% CAGR during the forecast period 2023-2030.
Typhoid Fever Vaccines Market size is projected to reach 8.445 billion by 2030
Shanghai Institute of Biological Products Co., Ltd., Bharat Biotech, Sanofi, GlaxoSmithKline, Paxvax Inc., Prokarium Ltd., Scandinavian Biopharma, China National Biotec Group